CancerLinQ
An Initiative of ConcertAI

Actionable Patients: FDA Approvals

Clinical Decision Support

CancerLinQ identifies patients who may qualify for a newly FDA-approved targeted therapy. This new addition to the Actionable Patients feature presents patients for clinician review to evaluate and confirm eligibility.

The FDA approvals feature is powered by structured biomarker results flowing into CancerLinQ. Upgrades to your CancerLinQ data integration may be required to realize the full impact of this new tool. Contact your account manager to learn more.



Intelligent Notifications Delivered to Your Inbox

CancerLinQ will notify clinical users when patients match to a therapy or new indication included in this feature. Weekly emails alert you if you have new patient matches. Seamlessly launch the FDA Approval tool directly from the email.

Organize and Manage Your Patients

Manage and monitor your patients based on their latest status: Track patients for whom you plan to prescribe the therapy in the future, set yourself timely reminders, and/or save patients for future review.

Monitor Your Partial Matches

Review patients who match to all clinical criteria as indicated on the FDA label except for biomarker results. Quickly enter missing results directly in the application to update the patient, or use tool to identify testing opportunities.

- Receive alerts and seamlessly launch the tool directly from your email
- Watch for potentially matching patients
- Organize your patients into worklists
- View patients who have received the therapy

For more information on SmartLinQ and the FDA Approvals tool, email info@cancerlinq.org.